Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Menlo Therapeutics

Menlo Therapeutics
2011 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
MNLO STOCK SYMBOL
$6.75 SHARE PRICE (As of Thursday Closing)
Description

Menlo Therapeutics Inc is a US-based late-stage biopharmaceutical company which focuses on the development and commercialization of Serlopitant for the treatment of pruritus associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The pipeline product of the company includes Prurigo Nodularis, Prurigo Dermatitis, Psoriasis and Refractory Chronic Cough.

Formerly Known As
Tigercat Pharma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 200 Cardinal Way
  • 2nd Floor
  • Redwood City, CA 94063
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Menlo Therapeutics’s full profile, request a free trial.

Menlo Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.74 - $12.00 $162M $6.97 -$2.50 90.4K 23.9M

Menlo Therapeutics Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 46,327 145,543
Revenue 10,143 10,640 4,582 674
EBITDA (60,953) (54,513) (29,585) (14,328)
Net Income (57,660) (51,445) (29,076) (14,068)
Total Assets 126,258 139,928 66,867 42,053
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Menlo Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Menlo Therapeutics‘s full profile, request access.

Request full access to PitchBook

Menlo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Menlo Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Menlo Therapeutics Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ritter Pharmaceuticals Formerly VC-backed Los Angeles, CA 0 000.00 000000000 000.00
000000000(00000000 Formerly VC-backed New York, NY 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000000 00000
000000 000000000 Formerly Angel backed New York, NY 00 00.000 00000000 00.000
To view this company’s complete list of competitors, request access »

Menlo Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Menlo Therapeutics‘s full profile, request access.

Request full access to PitchBook

Menlo Therapeutics Executive Team (10)

Name Title Board
Seat
Contact
Info
Steven Basta Chief Executive Officer, President & Board Member
Kristine Ball Senior Vice President, Corporate Strategy & Chief Financial Officer
Paul Kwon MD Chief Scientific Officer
Danine Summers Senior Vice President of Medical Affairs
Xiaoming Zhang Ph.D Senior Vice President of Nonclinical, CMC and Pre-Clinical and Pharmaceutical Development

1 Former Executive

You’re viewing 5 of 10 executives. Get the full list »

Menlo Therapeutics Board Members (10)

Name Representing Role Since Contact
Info
Aaron Royston MD venBio Board Member 000 0000
Albert Cha MD Vivo Capital Board Member 000 0000
David McGirr Self Board Member 000 0000
John Creecy Remeditex Ventures Board Member 000 0000
Paul Berns Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »